Bridgeway Capital Management, LLC Kinnate Biopharma Inc. Transaction History

Bridgeway Capital Management, LLC

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2023 Feb 14, 2024	SELL	$1.07 - $2.5 $56,710 - $132,500	-53,000 Reduced 36.73%	91,300 $216,000
Q3 2023 Nov 14, 2023	BUY	$1.38 - $3.31 $199,133 - $477,633	144,300 New	144,300 $202,000

292K

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgeway Capital Management, LLC with notifications on news.